Skip to main content
SpringerLink
Log in

Clinical Manifestations of Atherosclerosis

  • Chapter
  • First Online:
Inflammation and Atherosclerosis

Abstract

Cardiovascular disease (CVD) accounts for more than 4.3 million deaths in Europe representing 48% of all deaths (British Heart Foundation. European Cardiovascular Disease Statistics 2008) and is predicted to be the number one killer by 2020 in our ageing societies facing major societal and economic changes around the globe [1]. The clinical manifestations of CVD are diverse and comprise myocardial infarction, stroke, aortic aneurysms, renal artery stenosis and gangrene (Fig. 3.1). In Europe, the single most common cause of death is coronary artery disease (CAD; 21% of men and 21% of women) followed by stroke (11% of men and 17% of women) and the remaining manifestations of CVD (11% of men and 15% of women) (British Heart Foundation. European Cardiovascular Disease Statistics 2008). Despite major reductions in mortality obtained in the setting of acute myocardial infarction [2], morbidity due to CVD remains of eminent importance across the world as quantified with the Disability Adjusted Life Years (DALY) as an aggregate of years of life lost to due to premature death and years of healthy life lost to disability (British Heart Foundation. European Cardiovascular Disease Statistics 2008). Currently, 70% of clinical events cannot be prevented with available drug therapy including statins [3] and at least 10% of coronary events occur in apparently healthy individuals in the absence of major traditional risk factors [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367(9524):1747–1757

    PubMed  Google Scholar 

  2. ox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA 297(17):1892–1900

    PubMed  CAS  Google Scholar 

  3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278

    PubMed  CAS  Google Scholar 

  4. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB et al (2003) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290(7):891–897

    PubMed  Google Scholar 

  5. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847

    PubMed  CAS  Google Scholar 

  6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952

    PubMed  Google Scholar 

  7. Enos WF, Holmes RH, Beyer J (1986) Landmark article, July 18, 1953: Coronary disease among United States soldiers killed in action in Korea. Preliminary report, by. Enos WF, Holmes RH, Beyer J. JAMA 256(20):2859–2862

    Google Scholar 

  8. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M et al (1992) A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 85(1):391–405

    PubMed  CAS  Google Scholar 

  9. Cecchi E, Giglioli C, Valente S, Lazzeri C, Gensini GF, Abbate R et al (2011) Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis 214(2):249–256

    PubMed  Google Scholar 

  10. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B et al (2005) A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437(7057):426–431

    PubMed  CAS  Google Scholar 

  11. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI (2000) The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97(16):9052–9057

    PubMed  CAS  Google Scholar 

  12. Cheng C, van Haperen R, de Waard M, van Damme LC, Tempel D, Hanemaaijer L et al (2005) Shear stress affects the intracellular distribution of eNOS: direct demonstration by a novel in vivo technique. Blood 106(12):3691–3698

    PubMed  CAS  Google Scholar 

  13. Chappell DC, Varner SE, Nerem RM, Medford RM, Alexander RW (1998) Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 82(5):532–539

    PubMed  CAS  Google Scholar 

  14. Cheng C, Tempel D, van Haperen R, van der Baan A, Grosveld F, Daemen MJ et al (2006) Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113(23):2744–2753

    PubMed  Google Scholar 

  15. Tabas I, Williams KJ, Boren J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116(16):1832–1844

    PubMed  CAS  Google Scholar 

  16. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–95

    PubMed  CAS  Google Scholar 

  17. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6(7):508–519

    PubMed  CAS  Google Scholar 

  18. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH (2005) T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proceedings of the National Academy of Sciences of the United States of America, 21 Jan 21 2005

    Google Scholar 

  19. Gotsman I, Sharpe AH, Lichtman AH (2008) T-cell costimulation and coinhibition in atherosclerosis. Circ Res 103(11):1220–1231

    PubMed  CAS  Google Scholar 

  20. Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802–815

    PubMed  CAS  Google Scholar 

  21. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2009) Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol 31(1):23–33

    PubMed  CAS  Google Scholar 

  22. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K (2006) Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 203(5):1273–1282

    PubMed  CAS  Google Scholar 

  23. Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M et al (2009) Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J Exp Med 206(1):233–248

    PubMed  Google Scholar 

  24. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789):373–376

    PubMed  CAS  Google Scholar 

  25. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828):1111–1115

    PubMed  CAS  Google Scholar 

  26. Bedarida GV, Bushell E, Haefeli WE, Blaschke TF, Hoffman BB (1993) Responsiveness to bradykinin in veins of hypercholesterolemic humans. Circulation 88(6):2754–2761

    PubMed  CAS  Google Scholar 

  27. Charakida M, Masi S, Luscher TF, Kastelein JJ, Deanfield JE (2010) Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 31(23):2854–2861

    PubMed  Google Scholar 

  28. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T et al (2004) Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 110(18):2918–2923

    PubMed  Google Scholar 

  29. Halcox JP, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ et al (2009) Endothelial function predicts progression of carotid intima-media thickness. Circulation 119(7):1005–1012

    PubMed  Google Scholar 

  30. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106(6):653–658

    PubMed  Google Scholar 

  31. Pistoia F, Cipollone F, Ferri C, Sara M, Sudano I, Desideri GB (2010) Cyclooxygenase and atherosclerosis: a smoking area. Curr Pharm Des 16(23):2567–2571

    PubMed  CAS  Google Scholar 

  32. Linder L, Kiowski W, Buhler FR, Luscher TF (1990) Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 81(6):1762–1767

    PubMed  CAS  Google Scholar 

  33. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ et al (2008) Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31(4):776–782

    PubMed  CAS  Google Scholar 

  34. Sudano I, Virdis A, Taddei S, Spieker L, Corti R, Noll G et al (2007) Chronic treatment with long-acting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Hypertension 49(2):285–290

    PubMed  CAS  Google Scholar 

  35. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hurlimann D et al (2007) Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 25(4):785–791

    PubMed  CAS  Google Scholar 

  36. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697

    PubMed  Google Scholar 

  37. Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117(17):2262–2269

    PubMed  CAS  Google Scholar 

  38. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106(17):2184–2187

    PubMed  Google Scholar 

  39. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74(6):1399–1406

    PubMed  CAS  Google Scholar 

  40. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al (2007) Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, 2004, and Brussels, 2006. Cerebrovasc Dis 23(1):75–80

    Google Scholar 

  41. Bots ML, Baldassarre D, Simon A, de Groot E, O’Leary DH, Riley W et al (2007) Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J 28(4):398–406

    PubMed  Google Scholar 

  42. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115(4):459–467

    PubMed  Google Scholar 

  43. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH et al (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128(4):262–269

    PubMed  CAS  Google Scholar 

  44. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN (2002) ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106(16):2055–2060

    PubMed  CAS  Google Scholar 

  45. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH et al (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297(12):1344–1353

    PubMed  CAS  Google Scholar 

  46. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM (2000) Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101(6):598–603

    PubMed  CAS  Google Scholar 

  47. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ et al (2001) American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 37(5):1478–1492

    PubMed  CAS  Google Scholar 

  48. Ricciardi MJ, Meyers S, Choi K, Pang JL, Goodreau L, Davidson CJ (2003) Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. Am Heart J 146(3):507–512

    PubMed  Google Scholar 

  49. von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A et al (2004) Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110(12):1579–1585

    Google Scholar 

  50. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292(18):2217–2225

    PubMed  CAS  Google Scholar 

  51. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291(9):1071–1080

    PubMed  CAS  Google Scholar 

  52. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295(13):1556–1565

    PubMed  CAS  Google Scholar 

  53. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106(17):2200–2206

    PubMed  Google Scholar 

  54. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364(3):226–235

    PubMed  CAS  Google Scholar 

  55. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK et al (2010) Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 31(4):401–415

    PubMed  Google Scholar 

  56. Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I et al (2010) Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 31(14):1792–1801

    PubMed  Google Scholar 

  57. Sones FM Jr, Shirey EK (1962) Cine coronary arteriography. Mod Concepts Cardiovasc Dis 31:735–738

    PubMed  Google Scholar 

  58. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer M et al (2009) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360(3):213–224

    PubMed  CAS  Google Scholar 

  59. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH et al (1996) Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation 93(1):34–41

    PubMed  CAS  Google Scholar 

  60. Waters D, Craven TE, Lesperance J (1993) Prognostic significance of progression of coronary atherosclerosis. Circulation 87(4):1067–1075

    PubMed  CAS  Google Scholar 

  61. Gruntzig A (1976) Percutaneous recanalisation of chronic arterial occlusions (Dotter principle) with a new double lumen dilatation catheter (author’s transl). Rofo 124(1):80–86

    PubMed  CAS  Google Scholar 

  62. Serruys PW, Kutryk MJ, Ong AT (2006) Coronary-artery stents. N Engl J Med 354(5):483–495

    PubMed  CAS  Google Scholar 

  63. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000 May) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20(5):1262–1275

    PubMed  CAS  Google Scholar 

  64. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516

    PubMed  CAS  Google Scholar 

  65. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972

    PubMed  CAS  Google Scholar 

  66. Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC et al (2010) Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 122(10):949–957

    PubMed  Google Scholar 

  67. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28(13):1598–1660

    PubMed  CAS  Google Scholar 

  68. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29(23):2909–2945

    PubMed  Google Scholar 

  69. Steffel J, Luscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113(5):722–731

    PubMed  CAS  Google Scholar 

  70. Klingenberg R, Hansson GK (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 30(23):2838–2844

    PubMed  CAS  Google Scholar 

  71. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB et al (2010) Cellular actors, toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 31(12):1457–1469

    PubMed  CAS  Google Scholar 

  72. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE et al (2005) Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 111(11):1355–1361

    PubMed  CAS  Google Scholar 

  73. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML (2003) Acute myocardial infarction. Lancet 361(9360):847–858

    PubMed  Google Scholar 

  74. Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13–20

    PubMed  Google Scholar 

  75. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37(2):577–617

    PubMed  Google Scholar 

  76. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE et al (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6):549–559

    PubMed  CAS  Google Scholar 

  77. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431):331–337

    PubMed  CAS  Google Scholar 

  78. North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325(7):445–453

    Google Scholar 

  79. European Carotid Surgery Trialists’ Collaborative Group (1991) MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 337(8752):1235–1243

    Google Scholar 

  80. Ringleb PA, Allenberg J, Bruckmann H, Eckstein HH, Fraedrich G, Hartmann M et al (2006) 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368(9543):1239–1247

    PubMed  CAS  Google Scholar 

  81. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP et al (2006) Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355(16):1660–1671

    PubMed  CAS  Google Scholar 

  82. Ederle J, Dobson J, Featherstone RL, Bonati LH, van der Worp HB, de Borst GJ et al (2010) Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (international carotid stenting study): an interim analysis of a randomised controlled trial. Lancet 375(9719):985–997

    PubMed  Google Scholar 

  83. Kakkos SK, Tsolakis IA, Nicolaides AN (2010) Stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 363(18):1767, Author reply 1768

    PubMed  CAS  Google Scholar 

  84. Bonati LH, Ederle J, McCabe DJ, Dobson J, Featherstone RL, Gaines PA et al (2009) Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 8(10):908–917

    PubMed  Google Scholar 

  85. Ederle J, Bonati LH, Dobson J, Featherstone RL, Gaines PA, Beard JD et al (2009) Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 8(10):898–907

    PubMed  Google Scholar 

  86. Reiff T, Stingele R, Eckstein HH, Fraedrich G, Jansen O, Mudra H et al (2009) Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial. Int J Stroke 4(4):294–299

    PubMed  CAS  Google Scholar 

  87. Staub D, Schinkel AF, Coll B, Coli S, van der Steen AF, Reed JD et al (2010) Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques. JACC Cardiovasc Imaging 3(7):761–771

    PubMed  Google Scholar 

  88. Wahl A, Tai T, Praz F, Schwerzmann M, Seiler C, Nedeltchev K et al (2009) Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size. JACC Cardiovasc Interv 2(2):116–123

    PubMed  Google Scholar 

  89. Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E et al (2010) PLAATO (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 6(2):220–226

    PubMed  Google Scholar 

  90. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl 1):S1–S75

    PubMed  Google Scholar 

  91. Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285(19):2481–2485

    PubMed  CAS  Google Scholar 

  92. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):23–33

    Google Scholar 

  93. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients With peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47(6):1239–1312

    PubMed  Google Scholar 

  94. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG (1994) Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 90(4):1866–1874

    PubMed  CAS  Google Scholar 

  95. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB et al (2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109(7):523–530

    PubMed  CAS  Google Scholar 

  96. Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P (2002) Findings of the naftidrofuryl in quality of life (NIQOL) European study program. Int Angiol 21(1):20–27

    PubMed  CAS  Google Scholar 

  97. de Mast Q, Beutler JJ (2009) The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 27(7):1333–1340

    PubMed  Google Scholar 

  98. White CJ (2006) Catheter-based therapy for atherosclerotic renal artery stenosis. Circulation 113(11):1464–1473

    PubMed  Google Scholar 

  99. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE Jr (1994) Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. J Vasc Surg 19(2):250–257, Discussion 7–8

    PubMed  CAS  Google Scholar 

  100. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C et al (2009) Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361(20):1953–1962

    PubMed  Google Scholar 

  101. George JC, White CJ (2010) Renal artery stenting: lessons from ASTRAL (angioplasty and stenting for renal artery lesions). JACC Cardiovasc Interv 3(7):786–787

    PubMed  Google Scholar 

  102. Brown LC, Powell JT (1999) Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK small aneurysm trial participants. Ann Surg 230(3):289–296, Discussion 96–97

    PubMed  CAS  Google Scholar 

  103. Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM et al (2005) Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 352(23):2398–2405

    PubMed  CAS  Google Scholar 

  104. EVAR Trial Participants (2005) Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 365(9478):2179–2186

    Google Scholar 

  105. Choke E, Cockerill G, Wilson WR, Sayed S, Dawson J, Loftus I et al (2005) A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 30(3):227–244

    PubMed  CAS  Google Scholar 

  106. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286(11):1317–1324

    PubMed  CAS  Google Scholar 

  107. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987–1003

    PubMed  CAS  Google Scholar 

  108. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195–2207

    PubMed  CAS  Google Scholar 

  109. Koenig W, Ridker PM (2010) Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk > =5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 32:75–83

    PubMed  Google Scholar 

  110. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A et al (2006) Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 114(4):281–288

    PubMed  CAS  Google Scholar 

  111. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107(3):391–397

    PubMed  Google Scholar 

  112. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302(1):37–48

    PubMed  CAS  Google Scholar 

  113. Danesh J, Erqou S, Walker M, Thompson SG, Tipping R, Ford C et al (2007) The emerging risk factors collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 22(12):839–869

    PubMed  Google Scholar 

  114. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V et al (2009) Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38(1):217–231

    PubMed  Google Scholar 

  115. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M et al (2010) Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 30(5):946–952

    PubMed  CAS  Google Scholar 

  116. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117(23):3002–3009

    PubMed  CAS  Google Scholar 

  117. Camm AJ, Luscher TF, Serruys PW (2009) The ESC textbook of cardiovascular medicine, 2nd edn. Oxford University Press, Oxford, pp 99–236

    Google Scholar 

  118. Camm AJ, Luscher TF, Serruys PW (2009) The ESC textbook of cardiovascular medicine, 2nd edn. Oxford University Press, Oxford, pp 597–664, pp 919–953

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology and Cardiovascular Research, University Hospital and Institute of Physiology, Cardiovascular Research, University Zurich-Irchel, Zurich, Switzerland

    Thomas F. Lüscher

  2. Cardiology, Cardiovascular Center, University Hospital, Rämistrasse 100, CH-8091, Zurich, Switzerland

    Thomas F. Lüscher

Authors
  1. Roland Klingenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Hasun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Corti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas F. Lüscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas F. Lüscher .

Editor information

Editors and Affiliations

  1. Medical University Innsbruck, Peter-Mayr-Strasse 4 a, Innsbruck, 6020, Austria

    Georg Wick

  2. Laboratory of Autoimmunity, Division of Experimental Pathophysiology, Biocenter, Innsbruck Medical University, Schöpfstraße 41, Innsbruck, 6020, Austria

    Cecilia Grundtman

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag/Wien

About this chapter

Cite this chapter

Klingenberg, R., Hasun, M., Corti, R., Lüscher, T.F. (2012). Clinical Manifestations of Atherosclerosis. In: Wick, G., Grundtman, C. (eds) Inflammation and Atherosclerosis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0338-8_3

Download citation

Publish with us

Policies and ethics

Search

Navigation